4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992324-26-000004
EVP, CFO & CBO sold 114,367 shares at an average $83.00 ($9,492,596)
- EVP, CFO & CBO acquired 114,367 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Option exercise 10b5-1 | +74,367 | $8.44 | $627,657 | 74,367 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Option exercise 10b5-1 | +40,000 | $17.88 | $715,200 | 114,367 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −1,390 | $78.33 | $108,879 | 112,977 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −21,825 | $78.86 | $1,721,120 | 91,152 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −1,485 | $80.25 | $119,171 | 89,667 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −800 | $81.36 | $65,088 | 88,867 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −2,366 | $82.84 | $195,999 | 86,501 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −59,800 | $83.90 | $5,017,220 | 26,701 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −19,469 | $84.57 | $1,646,493 | 7,232 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Sale 10b5-1 | −7,232 | $85.54 | $618,625 | 0 | D |
| Derivatives | |||||||
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −74,367 | 10,399 | D | ||
| Savitz Ryan EVP, CFO & CBO | 2026-03-31 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,000 | 80,000 | D | ||
| Open-market sales · 114,367 sh · avg $83.00 · $9,492,596 | |||||||
Loading xslF345X06/ownership.xml…